top of page

ME RÁÐSTEFNA 28. SEPTEMBER 2017 - aukaefni



Peterson rannsóknir

Dr. Daniel Peterson, helstu rannsóknir

Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome


Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study


Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome


Cytokines in the Cerebrospinal Fluids of Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis


Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome


Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study


Distinct plasma immune signatures in ME/CFS are present early in the course of illness


A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome


A Multicenter Blinded Analysis Indicates No Association between Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and either Xenotropic Murine Leukemia Virus-Related Virus or Polytropic Murine Leukemia Virus


Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols


Neuromyasthenia and Chronic Fatigue Syndrome (CFS) in Northern Nevada/California: A Ten-Year Follow-Up of an [[1984 Incline Village chronic fatigue syndrome outbreak


Chronic Fatigue Syndrome and Disability


Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen


A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection


Please reload

Title: Therapeutic intervention and disease mechanisms in ME/CFS.

Øystein Fluge, MD, PhD, consultant in oncology and researcher, Dept. of Oncology, Haukeland University Hospital.


Ingrid Gurvin Rekeland, MD, physician in oncology training and research fellow, Dept. of Oncology, Haukeland University Hospital.  



In 2004-2007 we observed patients with long-standing ME/CFS who was diagnosed with lymphoma, and who experienced relief of ME/CFS symptoms after lymphoma therapy with chemotherapy and/or the therapeutic antibody rituximab.

We have since then performed research in ME/CFS and explored the therapeutic principle of B-cell depletion using the monoclonal anti-CD20 antibody rituximab in ME/CFS. First, a case series of three ME/CFS patients was performed, then a small randomized phase-II trial, and thereafter an open-label phase II study using prolonged B-cell depletion with rituximab maintenance treatment.

These studies indicate that a subgroup of ME/CFS patients may benefit from B-cell depletion therapy. To verify or refute the findings from these initial trials, a multi-center, randomized, double-blind phase III trial (rituximab maintenance versus placebo) with 151 ME/CFS patients is ongoing in Norway (finished by October 2017).

 In addition, after observing ME/CFS patients who got breast cancer and who reported improvement of ME/CFS symptoms after cytotoxic chemotherapy for breast cancer, an open-label phase II clinical trial exploring cyclophosphamide infusions in 40 ME/CFS patients is now finished. 

Analyses of both the rituximab (RituxME) and cyclophosphamide (CycloME) trials will be performed in autumn 2017.

Basic research is performed to elucidate possible disease mechanisms in ME/CFS, using biobank samples from patients included in the clinical trials. Using a metabolomics approach, our data indicate that ME/CFS patients have an “obstruction” in the central energy pathway, with inadequate use of glucose as energy source and early accumulation of lactic acid upon limited exertion, and with compensatory use of alternative sources (amino acids, fatty acids) for energy metabolism and oxidative phosphorylation.

Dr. Rekeland and dr. Fluge will during their talks give an overview of the clinical trials and of the laboratory work.

Fluge og Rekeland
bottom of page